Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD™ 2025 International ...

(the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001 ...

Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard ...

Reflections on a recent NEJM publication highlight the importance of identifying and addressing the pathologic process of ...

With Pathologic 3 set to release at an indeterminate date in 2025, a new demo titled Pathologic 3: Quarantine launched via ...

The overwhelming consensus amongst scientists is that there’s very little evidence to suggest that tracking your blood ...

REVEAL GENOMICS ®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical ...

SHANGHAI, China I March 17, 2025 I Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

This week’s games branch out in some new directions ...